Aegis Capital Sees a Solid Year Ahead for Rosetta Genomics (ROSG)

Aegis Capital analyst Robert LeBoyer reiterated a Buy rating and $3.50 price target on Rosetta Genomics (NASDAQ: ROSG) saying they are looking forward to 2017 as fundamentals continue to improve.

LeBoyer said the collaboration could add lung cancer diagnostic. "Rosetta has formed a collaboration to determine biomarkers that can predict response to Opdivo, a PD-1 immunotherapy. This is one of many potential applications of Rosetta's genetic profiling technology for selecting the best course of treatment for cancer patients. We believe the high cost of Opdivo could make this an important test to qualify patients for therapy."

The analyst also said cash is expected to be around $9.3 million at year end after the recent $5 million offering.

For an analyst ratings summary and ratings history on Rosetta Genomics click here. For more ratings news on Rosetta Genomics click here.

Shares of Rosetta Genomics closed at $0.45 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Banner Corporation (BANR) PT Lowered to $51 at Piper Sandler
• Soft UK retail sales unlikely to change BoE stance: analyst